A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 29 May 2019 to 3 Jun 2019.
    • 07 Jun 2017 Planned primary completion date changed from 20 Sep 2017 to 25 Sep 2017.
    • 18 Apr 2017 Planned End Date changed from 1 Dec 2018 to 29 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top